Posts Tagged: "WIPO"

Most U.S. patent practitioners are keenly aware of the foreign filing license requirement for filing of U.S. patent applications abroad. Since it is common for U.S. based companies to file a U.S. priority patent application and take advantage of the one-year grace period for foreign filing, a foreign filing license is typically issued without much thought to the matter. Given the propensity for international companies and many universities to routinely carry out inventive activities in multiple countries by inventors of varied citizenships, the opportunities to run afoul of foreign filing license requirements is of growing concern, and this concern extends well beyond the walls of the U.S. Patent and Trademark Office (USPTO).

The World Intellectual Property Organization (WIPO) established World IP Day (WIPD) 19 years ago to celebrate the day on which the WIPO Convention entered into force: April 26, 1970. With nearly five decades under its belt, WIPO has had its successes and scandals, but there can be no doubt that IP rights are more harmonized now than ever before. This year’s WIPD theme is “Reach for Gold: IP and Sports.” While the topic may seem slightly off-mark to some, with so much else to talk about in the context of a rapidly-evolving global digital economy in which IP rights are becoming both more crucial and increasingly threatened in many jurisdictions, it does underscore the degree to which IP permeates industries and facilitates consumer experiences.In honor of World IP Day, we asked the experts to weigh in on how far we’ve come in the two decades since the holiday was established, and what the future holds. As usual, there were optimists, pessimists, and those in between. Here’s what they had to say.

Brexit has been postponed and will not now happen at midnight on March 29, 2019.The UK’s House of Commons has twice voted against the Withdrawal Agreement and Political Declaration, which were agreed between the UK Government and the European Union in November 2018. It is not clear at this stage whether Members of Parliament (MPs) will support the Agreement if and when it is put before them again. The UK Government updated its guidance on IP and Brexit on March 22 2019.The most important point for IP rights holders is that on Brexit day, whenever that is, unitary EU rights (notably EU trademarks and registered Community designs) will cease to cover the UK, unless there is an agreement to the contrary.

This week in Other Barks & Bites: the Supreme Court asks for the U.S. Solicitor General’s view on whether patents that claim a method of medically treating a patient automatically satisfy Section 101; a jury gives Qualcomm a win in its ongoing patent battle with Apple; the World Intellectual Property Office announces record-breaking totals for international patent applications and cybersquatting actions; Cisco avoids a nearly $60 million damages award at the Federal Circuit; McDonald’s appeals its loss in the EU over its Big Mac trademark; Tesla files trade secret lawsuits against former employees; Peloton faces a copyright suit from music publishers who are seeking $150 million; and Google gets another billion-dollar-plus fine from antitrust regulators in the EU.

According to the World Blind Union, of the millions of books published each year, approximately only 1-7 percent are made available to those who are visually impaired. On January 28, President Donald J. Trump signed the documents for the United States to ratify the Marrakesh Treaty to Facilitate Access to Published Works for Persons Who Are Blind, Visually Impaired, or Otherwise Print Disabled. The treaty was adopted in Marrakesh, Morocco in 2013. The goal of the copyright treaty is to increase access to printed materials for those with visual or other disabilities. The treaty is administered by the World Intellectual Property Organization (WIPO).

This week in Other Barks & Bites: Huawei is in hot water with both the U.S. and UK governments, while Qualcomm has just completed a new patent licensing deal with Huawei; IBM tops a new global list for most artificial intelligence-related patent applications filed; Apple files another appeal of a major patent infringement damages award handed to VirnetX in the Eastern District of Texas; and see how the biggest IP players are doing Wall Street.

International trademarks were once only necessary for large scale businesses and corporations. In today’s global marketplace, however, nearly any business, especially a business with online exposure, should consider filing for an international trademark. With the rise of counterfeiters and cybersquatters in other countries, like China, protecting your brand at home and across the world may be more critical than ever. Having a strategic trademark plan on a global scale will ensure your brand’s value will be managed by you, not an imposter from a country half the world away. Consider the following as you begin the process to register your trademark internationally.

Effective December 1, 2018, electronic retrieval of priority documents between the United States Patent and Trademark Office (USPTO) and the Korean Intellectual Property Office (KIPO) will be managed via the World Intellectual Property Organization (WIPO) Digital Access Service (DAS), in accordance with the WIPO DAS agreement established on April 20, 2009. The certified copy requirement is considered satisfied when a foreign priority document is retrieved electronically via the WIPO DAS service during pendency of the U.S. application. There is no fee for this service and participation for a particular application is voluntary.

Bloomberg recently published an article providing data analysis on Chinese patent applications to claim that, while China receives more patent applications than any country, “most are worthless.” If you were trying to usher in a culture change, moving from no patent system just a few decades ago to a thriving and high functioning patent system, you would look to incentivize your own citizens and corporations to file patent applications. That is precisely what China has done and is continuing to do. Thus, the mantra about Chinese patent applications being worthless, or nothing of a concern because they are overwhelmingly only filed in China, completely misses the enormity of the change taking place in China, and why it bodes well for the Chinese moving forward.

The World Intellectual Property Organization (WIPO) has published its annual World Intellectual Property Indicators. For the second consecutive year, the number of design applications filed worldwide continued to grow, with an estimated 963,100 applications filed in total globally. The 2016 growth rate was 10.4%, following 2015’s more modest growth rate of 2.3% and 2014’s 10.2% drop in applications. 90% of the growth in 2016 can be attributed to increased filings in China.

Enforcement of trademark rights in China is an ongoing issue faced by numerous corporations.  Invalidating or canceling a trademark registration in the Chinese market is time-consuming and costly.  The best way to defend your company’s valuable intellectual property assets is to put in place as many protections as possible.  If your company owns a creative design mark, consider going beyond the standard trademark registration and getting the “super trademark” by obtaining copyright registration for this artistic design element.

The patent boom China has been experiencing is easy to explain. China as a country has been unwavering in its support for domestic patent production in recent years. Indeed, the Chinese government has been actively encouraging not only increased innovation that makes it more likely there will be patentable innovations, but that government has been aggressively incentivizing increased patent filings. Incentives include subsidizing patent filing fees, providing rewards for patent filings, and tax credits that are tied to patent output. In many ways, China’s innovation economy is a near photo-negative of the current iteration of the U.S. patent system.

One of the questions that gets asked this time of year, when the world is busy flipping the calendar from one year to the next, is “What are you looking forward to in the new year?” For patent owners operating in the U.S., however, it may be better to ask, “What are you looking ahead to in 2018?” Looking forward would seem to denote a sense of optimism and such optimism has been in short supply among those in the tech space who don’t have the deep wallets to withstand the costs of pursuing infringers, including those costs incurred by the efficient infringer cartel’s use of the Patent Trial and Appeal Board (PTAB).

Globally, a total of 3.1 million patent applications were filed with patent offices worldwide during 2016, an increase of 8.3 percent over 2015’s filing numbers and the seventh straight year in which saw a year-over-year increase in global patent application filings. About 1.3 million patent applications were filed with China’s State Intellectual Property Office (SIPO), a record number of patent applications received by any patent office in a single year. China’s 2016 patent application total is greater than the combined total of patent applications filed in 2016 in the United States (605,571), Japan (318,381), South Korea (208,830) and Europe (159,358). These five jurisdictions accounted for 84 percent of all patent applications filed during 2016.

Protecting innovation through patents is the lifeblood of the global pharmaceutical industry. Without patents the world and its expanding population would be deprived of new and, ultimately, affordable life-saving medicines. Nevertheless, the high profitability of pharma companies has prompted an increasingly widespread (and often ill-informed) political debate on patents. This is not just because of mounting health costs but also the lack of access to life-saving medicines in developing countries. But this argument on the alleged high costs caused by patents falls short because most patents for essential medicines on the World Health Organization (WHO) list are expired and are available at generic medicine prices. Even so, patients in countries where they are most needed do not have access to generics. And the reasons for this are multiple, not least inadequate, poorly-funded healthcare systems.